UARK 2006-15: A phase III randomized study of tandem transplants with or without bortezomib (Velcade) and thalidomide (Thalomid) to evaluate its effect on response rate and durability of response in multiple myeloma patients.

Trial Profile

UARK 2006-15: A phase III randomized study of tandem transplants with or without bortezomib (Velcade) and thalidomide (Thalomid) to evaluate its effect on response rate and durability of response in multiple myeloma patients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2011 Planned End Date changed from 1 Dec 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Nov 2010 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top